<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">OHNO, SATOSHI</style></author><author><style face="normal" font="default" size="100%">DOHI, SATOSHI</style></author><author><style face="normal" font="default" size="100%">OHNO, YUMIKO</style></author><author><style face="normal" font="default" size="100%">KYO, SATORU</style></author><author><style face="normal" font="default" size="100%">SUGIYAMA, HARUO</style></author><author><style face="normal" font="default" size="100%">SUZUKI, NOBUTAKA</style></author><author><style face="normal" font="default" size="100%">INOUE, MASAKI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunohistochemical Detection of WT1 Protein in Endometrial Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1691-1695</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The Wilms' tumor gene WT1 is overexpressed in various kinds of solid tumors. However, it remains unclear whether WT1 plays a pathophysiological role in endometrial cancer. Patients and Methods: A series of 70 endometrial cancer patients who had undergone a curative resection was studied to determine the correlation between WT1 expression, clinicopathological characteristics and prognosis. Tissue specimens were evaluated for WT1 expression by immunohistochemistry. Results: The expression of WT1 was strong in 31 patients (44%) and weak in 39 patients (56%). WT1 overexpression was associated with advanced FIGO stage (p=0.0266), myometrial invasion (p=0.0477) and high-grade histological differentiation (p=0.0049). The expression level of WT1 was found to be a significant predictor of disease relapse in univariate analysis (p=0.0233), but not in multivariate analysis (p=0.4757). Conclusion: These results suggested that tumor-produced WT1 provided additional prognostic information in endometrial cancer patients.</style></abstract></record></records></xml>